SCHEMBL3246173

SCHEMBL3246173

COc1ccc(S(=O)(=O)N(Cc2nnn[nH]2)c2ccc(Cl)cc2C(=O)c2ccccc2Cl)cc1OC

nearest known ligand 0.46

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
PKM P14618 1/20 0.46
HCRTR2 O43614 9/20 0.44
HCRTR1 O43613 6/20 0.44
SMN1; SMN2 Q16637 2/20 0.41
ALDH1A1 P00352 1/20 0.41
HPGD P15428 1/20 0.41
HTT P42858 1/20 0.41
MCOLN3 Q8TDD5 2/20 0.41
POLB P06746 1/20 0.41
MAPT P10636 1/20 0.39
OXTR P30559 2/20 0.38
AVPR1A P37288 1/20 0.38
HIF1A Q16665 1/20 0.38
EPAS1 Q99814 1/20 0.38
FLT1 P17948 1/20 0.38
FLT4 P35916 1/20 0.38
KDR P35968 1/20 0.38
LMNA P02545 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8273289 0.84 PKM (0.43) PKMHCRTR2HCRTR1SMN1; SMN2ALDH1A1
SCHEMBL3255615 0.83 PKM (0.43) PKMHCRTR2HCRTR1SMN1; SMN2ALDH1A1
SCHEMBL8989867 0.81 PKM (0.70) PKMHCRTR2HCRTR1SMN1; SMN2ALDH1A1
SCHEMBL3249396 0.81 PKM (0.51) PKMHCRTR2HCRTR1SMN1; SMN2MCOLN3
SCHEMBL3253202 0.79 C5AR1 (0.55) PKMHCRTR2HCRTR1SMN1; SMN2MCOLN3
SCHEMBL3251584 0.77 PKM (0.42) PKMHCRTR2HCRTR1SMN1; SMN2ALDH1A1
SCHEMBL8989874 0.77 PKM (0.56) PKMHCRTR2HCRTR1SMN1; SMN2ALDH1A1
SCHEMBL8989923 0.75 MCOLN3 (0.74) PKMHCRTR2HCRTR1ALDH1A1HTT
SCHEMBL8989976 0.75 PKM (0.60) PKMHCRTR2HCRTR1SMN1; SMN2ALDH1A1
SCHEMBL8989862 0.75 PKM (0.60) PKMHCRTR2HCRTR1ALDH1A1MCOLN3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1776347-B1 SULPHONAMIDE DERIVATIVES, THEIR PREPARATION AND THEIR THERAPEUTIC APPLICATION SANOFI AVENTIS (FR) 2010-05-26 EP disclosed
US-7396958-B2 Sulphonamide derivatives, their preparation and their therapeutic application SANOFI AVENTIS (FR) 2008-07-08 US disclosed
US-20070185136-A1 SULPHONAMIDE DERIVATIVES, THEIR PREPARATION AND THEIR THERAPEUTIC APPLICATION SANOFI-AVENTIS (FR) 2007-08-09 US disclosed
EP-1776347-A1 SULPHONAMIDE DERIVATIVES, THEIR PREPARATION AND THEIR THERAPEUTIC APPLICATION Sanofi-Aventis (FR) 2007-04-25 EP disclosed
WO-2006024779-A1 SULPHONAMIDE DERIVATIVES, THEIR PREPARATION AND THEIR THERAPEUTIC APPLICATION SANOFI-AVENTIS (FR) 2006-03-09 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070185136-A1 SULPHONAMIDE DERIVATIVES, THEIR PREPARATION AND THEIR THERAPEUTIC APPLICATION HCRTR2, GIPR, SSTR2 PKM 2524/4885HCRTR2 1/4885HCRTR1 6/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.